Identification and Validation of a Necroptosis-Related Prognostic Signature for Kidney Renal Clear Cell Carcinoma

Figure 4

Immunotherapy/chemotherapy analysis among subtypes. (a) The expression differences of 21 immune checkpoint inhibitors (ICI) among three subtypes. (b) TIDE analysis of the immunotherapy response differences among three subtypes. (c) Patients in C3 were more sensitive to sunitinib, cyclopamine, imatinib, and crizotinib. (c) Samples in C2 were more sensitive to erlotinib, sorafenib, dasatinib, and saracatinib. ns means no significance, means <0.05, means <0.01, means <0.001, and means <0.0001.

(a)

(b)

(c)

(d)